EScitalopram PIndolol ONset of Action (ESPION)

Antidepressant Effect of Escitalopram: Delay of Onset. Clinical Randomized Double-blinded Study With Three Parallel Treatment Groups (Escitalopram 20mg vs Escitalopram 30mg vs Escitalopram 20 mg + Pindolol 15 mg/Day

The main purpose of this study is to determine whether the antidepressant response of escitalopram 30mg/day or escitalopram 20mg/day + pindolol, a beta blocker, is different (faster) compared to a standard dose of escitalopram 20mg/day.

Study Overview

• Status: Terminated
• Conditions: Unipolar Depression
• Intervention / Treatment: Drug: escitalopram, pindolol; Drug: escitalopram; Drug: escitalopram

Detailed Description

Antidepressant drug therapy is the primary therapeutic treatment option in moderate to severe Major Depressive Disorder. However, clinically significant antidepressant response needs sustained treatment during weeks to months. Indeed, in the largest effectiveness study conducted to date (STAR*D study) involving nearly 3000 depressed outpatients, only about one third of those who ultimately responded did so after 6 weeks of drug treatment and for most patients longer treatment periods were necessary. This delay implies prolonged suffering for the patients and their families. By its antagonist action on the serotonin 1A receptor pindolol is hypothesized to reduce the down-regulation mechanisms of antidepressants. It is therefore expected that addition of pindolol to escitalopram will shorten the therapeutic response. Clinical and preclinical data indicate that escitalopram at 30 mg/day might be more effective and perhaps be associated with a faster onset of action than 20mg. For this purpose the speed of action will be compared between three blindly randomized samples:

• escitalopram 20mg per day + placebo
• escitalopram 30mg per day + placebo
• escitalopram 20mg per day + pindolol 15mg per day (two doses of 7.5mg during 14 days).

Subjects will be followed for 6 weeks. The dose of 15mg pindolol per day (during 14 days) is based on the optimal occupancy of the serotonin 1A receptor.

At inclusion all subjects will be assessed by a trained psychiatrist using the SCID I mood disorder part which is based on DSM IV criteria, and by means of the French version of the MINI. Severity of depression will be assessed using the MADRS clinician rated and self-report questionnaire, and the French version of the QIDS.

Each week subjects will be assessed using the two versions of the Montgomery-Asberg Depression Rating Scale (MADRS) and the HCL-32 a self-report questionnaire assessing hypomania.

It is planned to include 135 patients during the three years of the study duration resulting in 45 subjects in each group.

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Switzerland
  • Geneva, Switzerland, 1205
    • Centre de Thérapies Breves (CTB), Secteur Jonction

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• patients aged between 18 and 65 years old
• patients suffering from major depression according to DSM-IV with a MADRS score of at least 25 and not treated by an antidepressant at the time of inclusion with the exception of non-responders to antidepressant for a period of at least 6 weeks or not tolerating an ongoing antidepressant necessitating a change of the antidepressant(excluding fluoxetine and irreversible MAOI)
• informed consent

Exclusion criteria:

• any other Axis I disorder excluding anxiety disorder not dominating the clinical picture, nicotine abuse
• non-responders to escitalopram in the past
• already taking pindolol
• pregnancy and breast feeding
• contraindication to one of the two treatments (medical conditions, drug treatments)
• significant somatic comorbidity interfering with the study procedures
• high risk of suicidality
• women of childbearing age not having a safe means of contraception

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: escitalopram 20mg + pindolol 15mg; Days 1-2: escitalopram 10 mg + placebo, days 3-42: escitalopram 20mg + placebo Days 1-14: pindolol 15 mg, days 15-17: pindolol 7.5 mg	Drug: escitalopram, pindolol; escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17; Other Names: escitalopram/Cipralex; pindolol/Viskene
Active Comparator: Escitalopram 30 mg; Days 1-2: escitalopram 10 mg+ placebo, days 3-4 escitalopram 20 mg + placebo, days 5-42: escitalopram 30mg+ placebo	Drug: escitalopram; escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg; Drug: escitalopram; escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
Active Comparator: escitalopram 20 mg; days 1-2: escitalopram 10 mg+ placebo, days 3-42: escitalopram 20 mg + placebo	Drug: escitalopram; escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg; Drug: escitalopram; escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
MADRS score change between baseline and 2 weeks of treatment	Differences in MADRS score changes (baseline-day 14) between treatment groups	day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response/remission (MADRS) at 6 weeks	% of patients with a given treatment which meet response/remssion criteria after 6 weeks of treatment, based on MADRS	day 42
Adverse events	Frequence of adverse events in treatment groups	See primary outcome measure
Correlation of drug level of pindolol and/or escitalopram and clinical outcome (primary outcome) between treatment groups		Day 10

Collaborators and Investigators

• Sponsor: Markus KOSEL
• Collaborators: University Hospital, Geneva; H. Lundbeck A/S; University Hospital, Basel, Switzerland; University of Lausanne Hospitals
• Investigators: Principal Investigator: Markus Kosel, MD-PhD, University Hospital, Geneva

Study record dates

Study Major Dates

• Study Start: October 1, 2010
• Primary Completion (Actual): April 1, 2013
• Study Completion (Actual): June 1, 2013

Study Registration Dates

• First Submitted: October 7, 2010
• First Submitted That Met QC Criteria: October 12, 2010
• First Posted (Estimate): October 13, 2010

Study Record Updates

• Last Update Posted (Estimate): May 27, 2015
• Last Update Submitted That Met QC Criteria: May 26, 2015
• Last Verified: May 1, 2015

More Information

Terms related to this study

• Keywords: unipolar depression, escitalopram, pindolol
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Mood Disorders; Depression; Depressive Disorder; Physiological Effects of Drugs; Adrenergic beta-Antagonists; Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Vasodilator Agents; Parasympatholytics; Autonomic Agents; Peripheral Nervous System Agents; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Psychotropic Drugs; Serotonin Uptake Inhibitors; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Serotonin Agents; Antidepressive Agents; Serotonin Antagonists; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Anti-Dyskinesia Agents; Citalopram; Dexetimide; Pindolol
• Other Study ID Numbers: CER 09-054, Psy 09-004